INCY Incyte
- Official Name: INCYTE CORPORATION
- Headquarters: 1801 Augustine Cut-Off, WILMINGTON, DE, 19803 US
- CEO: Herve Hoppenot
- Website: incyte.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Lost by 0.772 | (1.825) - (1.053) | ||
| 2025-07-17 | 1 | Lost by 0.921 | (4.129) - (3.208) | ||
| 2025-07-23 | 1R | Won by 2.168 | 2.275 - 0.107 | ||
| 2025-07-24 | 2 | Won by 9.051 | 3.899 - (5.152) | ||
| 2025-07-31 | 3 | Won by 9.348 TOTW | 6.143 - (3.205) | ||
| 2025-08-06 | 2R | Won by 2.772 | 0.061 - (2.711) | ||
| 2025-08-07 | 4 | Won by 7.869 | 3.936 - (3.933) | ||
| 2025-08-07 | 1R | Won by 0.120 | 0.809 - 0.689 | ||
| 2025-08-14 | 5 | Won by 7.970 | 8.388 - 0.418 | ||
| 2025-08-20 | 3R | Won by 3.525 | 0.824 - (2.701) | ||
| 2025-08-21 | 6 | Won by 1.163 | 1.589 - 0.426 | ||
| 2025-08-21 | 2R | Won by 1.369 | 0.627 - (0.742) | ||
| 2025-08-28 | 7 | Lost by 3.613 | (3.158) - 0.455 | ||
| 2025-09-03 | 4R | Won by 1.718 | 1.132 - (0.586) | ||
| 2025-09-04 | 8 | Lost by 1.206 | 2.189 - 3.395 | ||
| 2025-09-04 | 3R | Lost by 1.561 | (1.820) - (0.259) | ||
| 2025-09-11 | 9 | Won by 2.434 | 0.887 - (1.547) | ||
| 2025-09-17 | 5R | Lost by 2.032 | 1.080 - 3.112 | ||
| 2025-09-18 | 10 | Won by 4.818 | (0.195) - (5.013) | ||
| 2025-09-25 | 11 | Lost by 3.952 | (4.968) - (1.016) | ||
| 2025-10-02 | 12 | Won by 2.106 | 5.765 - 3.659 | ||
| 2025-10-09 | 13 | Won by 0.577 | (1.779) - (2.356) | ||
| 2025-10-16 | 14 | Won by 3.848 | 3.085 - (0.763) | ||
| 2025-10-23 | 15 | Lost by 1.251 | 2.188 - 3.439 |
Latest News
ChartMill - 2026-08-27
Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience
INCYTE (INCY) passes Minervini Trend Template & High Growth screen with strong earnings, sales, RS 93. Setup score 6/10 means wait for better entr...
Show more
SeekingAlpha - 2026-08-26
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
SeekingAlpha - 2026-08-25
Don't Sleep On Software
Yahoo - 2026-08-24
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SeekingAlpha - 2026-08-23
Prelude Therapeutics: A Prognosis After Year-Long Rally
SeekingAlpha - 2026-08-22
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
Benzinga - 2026-08-20
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Benzinga - 2026-08-20
Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
SeekingAlpha - 2026-08-20
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Benzinga - 2026-08-20
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
Yahoo - 2026-08-20
7 Growth Stocks Holding Up in a Tough Market
SeekingAlpha - 2026-08-19
Silence Therapeutics: Making Some Recent Noise
Yahoo - 2026-08-18
Incyte Stock: Is Wall Street Bullish or Bearish?
Benzinga - 2026-08-17
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
ChartMill - 2026-08-17
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
SeekingAlpha - 2026-08-16
IHF: Healthcare Dashboard For August
Yahoo - 2026-08-13
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
Yahoo - 2026-08-12
Incyte Sales Growth Drives Share Price Gains
Yahoo - 2026-08-07
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo - 2026-08-06
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
Yahoo - 2026-08-05
REGN or INCY: Which Is the Better Value Stock Right Now?
Benzinga - 2026-08-04
Mizuho Maintains Outperform on Incyte, Raises Price Target to $137
SeekingAlpha - 2026-08-03
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Benzinga - 2026-08-03
Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga - 2026-08-03
Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155
Benzinga - 2026-08-02
Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years
Yahoo - 2026-08-01
European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)
Yahoo - 2026-08-01
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
Yahoo - 2026-07-29
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod
Benzinga - 2026-07-29
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109
Benzinga - 2026-07-29
Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Benzinga - 2026-07-29
Guggenheim Maintains Buy on Incyte, Raises Price Target to $150
Yahoo - 2026-07-29
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Benzinga - 2026-07-29
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130
Benzinga - 2026-07-29
Top 3 Health Care Stocks That May Implode This Month
Benzinga - 2026-07-29
Barclays Maintains Overweight on Incyte, Raises Price Target to $139
Benzinga - 2026-07-29
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $150
Benzinga - 2026-07-29
Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients
ChartMill - 2026-07-28
Exploring the top movers within the S&P500 index during today's session.
Yahoo - 2026-07-28
Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
ChartMill - 2026-07-28
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.
Yahoo - 2026-07-28
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Benzinga - 2026-07-28
Incyte Says It's No Longer A One-Drug Story
SeekingAlpha - 2026-07-28
Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation
Yahoo - 2026-07-28
Incyte Q2 Earnings Call Highlights
Yahoo - 2026-07-28
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
ChartMill - 2026-07-28
Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut
SeekingAlpha - 2026-07-28
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Yahoo - 2026-07-28
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
Yahoo - 2026-07-28
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly
Benzinga - 2026-07-28
A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options
Benzinga - 2026-07-28
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition
Yahoo - 2026-07-28
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
SeekingAlpha - 2026-07-28
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Benzinga - 2026-07-28
ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’
Benzinga - 2026-07-28
Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate
Benzinga - 2026-07-28
Incyte Raises FY2026 Sales Guidance from $4.770B-$4.940B to $5.130B-$5.260B vs $5.712B Est
ChartMill - 2026-07-27
INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings
Yahoo - 2026-07-27
What To Expect From Incyte’s (INCY) Q2 Earnings
Yahoo - 2026-07-25
Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics
Yahoo - 2026-07-24
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
ChartMill - 2026-07-24
INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup
Benzinga - 2026-07-23
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $110
Benzinga - 2026-07-23
Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $104
Yahoo - 2026-07-21
HALO Inks Deal With INCY to Support Cancer Therapy Development
Yahoo - 2026-07-21
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
SeekingAlpha - 2026-07-21
Tracking Baker Brothers Portfolio: Q1 2026 Update
Benzinga - 2026-07-21
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target
Yahoo - 2026-07-20
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development
ChartMill - 2026-07-20
Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation
Benzinga - 2026-07-20
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody
SeekingAlpha - 2026-07-19
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data
SeekingAlpha - 2026-07-17
Incyte: Profitable Biotech That Could Be Close To Exploding
Benzinga - 2026-07-17
Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026
SeekingAlpha - 2026-07-16
Steven Cress' Top 2 Stocks H2 2026
Yahoo - 2026-07-16
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
Yahoo - 2026-07-15
What to Expect From Incyte's Q2 2026 Earnings Report
Yahoo - 2026-07-15
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
SeekingAlpha - 2026-07-14
A Fresh Look At Syndax Pharmaceuticals
Benzinga - 2026-07-14
Barclays Maintains Overweight on Incyte, Raises Price Target to $134
Yahoo - 2026-07-13
Sector Update: Healthcare Stocks Advance Late Afternoon
Yahoo - 2026-07-13
Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
Yahoo - 2026-07-13
Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3
Yahoo - 2026-07-13
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis
Yahoo - 2026-07-13
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
Yahoo - 2026-07-13
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
CNBC - 2026-07-13
The 10 best state economies in America in 2026
Benzinga - 2026-07-13
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112
SeekingAlpha - 2026-07-09
Steven Cress' Top 10 Stocks For 2026 (Mid-Year Review)
Yahoo - 2026-07-08
2 Fast-Growing Pharmaceutical Stocks to Buy Now
SeekingAlpha - 2026-07-08
Biotech Euphoria Driven By Fundamentals
Yahoo - 2026-07-08
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside
Yahoo - 2026-07-08
Incyte to Report Second Quarter Financial Results
Benzinga - 2026-07-07
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99
Yahoo - 2026-07-06
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Yahoo - 2026-07-03
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
Yahoo - 2026-07-03
1 Mid-Cap Stock to Research Further and 2 We Avoid
SeekingAlpha - 2026-07-02
Top 10 Quant Stocks Of 2026 Up Nearly 70%
Yahoo - 2026-07-01
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales
Yahoo - 2026-06-29
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Yahoo - 2026-06-29
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Yahoo - 2026-06-29
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
ChartMill - 2026-06-29
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side
SeekingAlpha - 2026-06-29
Incyte: New Catalysts Support Another Leg Higher
Yahoo - 2026-06-27
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs
Yahoo - 2026-06-26
Lilly, J&J and AbbVie Hit New Highs
Benzinga - 2026-06-26
UBS Maintains Neutral on Incyte, Raises Price Target to $113
Yahoo - 2026-06-26
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Benzinga - 2026-06-26
Incyte Announces EMA CHMP Positive Opinion Recommending Approval Of Opzelura Cream For Moderate Atopic Dermatitis; Application Now Referred To European Commission For Final Action
SeekingAlpha - 2026-06-24
MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment
Yahoo - 2026-06-22
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks
Benzinga - 2026-06-22
Truist Securities Maintains Hold on Incyte, Raises Price Target to $105
Yahoo - 2026-06-22
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Yahoo - 2026-06-22
Incyte Stock: Is INCY Outperforming the Healthcare Sector?
Benzinga - 2026-06-22
Micron To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga - 2026-06-22
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Benzinga - 2026-06-22
BMO Capital Upgrades Incyte to Market Perform, Raises Price Target to $94
SeekingAlpha - 2026-06-18
Abivax: Safety Signals Loom Ahead Of The NDA Submission
ChartMill - 2026-06-15
Top S&P500 movers in Monday's session
ChartMill - 2026-06-15
Monday's session: top gainers and losers in the S&P500 index
Yahoo - 2026-06-15
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
ChartMill - 2026-06-15
Which S&P500 stocks are gapping on Monday?
Yahoo - 2026-06-14
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Yahoo - 2026-06-11
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity
Yahoo - 2026-06-11
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
Yahoo - 2026-06-10
Why Incyte (INCY) Stock Is Up Today
ChartMill - 2026-06-10
Top S&P500 movers in Wednesday's session
Yahoo - 2026-06-10
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Yahoo - 2026-06-10
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
SeekingAlpha - 2026-06-09
Incyte: I Am Moving From Hold To Buy
Yahoo - 2026-06-09
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Benzinga - 2026-06-09
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Yahoo - 2026-06-09
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
CNBC - 2026-06-09
Calls of the Day: Health Care and Materials
Benzinga - 2026-06-09
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $140
SeekingAlpha - 2026-06-09
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Yahoo - 2026-06-08
Sector Update: Healthcare Stocks Decline Late Afternoon
Yahoo - 2026-06-08
Incyte To Acquire Vega Therapeutics For Up To $2 Billion
SeekingAlpha - 2026-06-08
Incyte Corporation (INCY) Vega Therapeutics, Inc. - M&A Call - Slideshow
Yahoo - 2026-06-08
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Yahoo - 2026-06-08
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
SeekingAlpha - 2026-06-08
Incyte Corporation (INCY) M&A Call Transcript
Benzinga - 2026-06-08
Incyte Strikes Agreement To Acquire Vega Therapeutics For $1.25B
Yahoo - 2026-06-05
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
Yahoo - 2026-06-05
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)?
ChartMill - 2026-06-05
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability
ChartMill - 2026-06-03
Wednesday's session: top gainers and losers in the S&P500 index
ChartMill - 2026-06-03
These S&P500 stocks are moving in today's session
Yahoo - 2026-06-02
Centene, Deckers and 14 Other ‘Dividend Hopefuls’
Yahoo - 2026-05-29
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Yahoo - 2026-05-28
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Yahoo - 2026-05-28
3 Profitable Stocks for Long-Term Investors
Yahoo - 2026-05-27
PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential Thrombocythemia
Yahoo - 2026-05-25
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
ChartMill - 2026-05-23
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup
Benzinga - 2026-05-22
Bernstein Initiates Coverage On Incyte with Market Perform Rating, Announces Price Target of $99
Yahoo - 2026-05-22
How Incyte’s AI-Powered R&D Partnerships At Incyte (INCY) Has Changed Its Investment Story
Benzinga - 2026-05-21
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $135 Price Target
SeekingAlpha - 2026-05-19
Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Yahoo - 2026-05-19
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
SeekingAlpha - 2026-05-13
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Yahoo - 2026-05-12
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Yahoo - 2026-05-11
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24
Yahoo - 2026-05-10
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations
SeekingAlpha - 2026-05-08
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Yahoo - 2026-05-08
Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)?
Yahoo - 2026-05-07
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Yahoo - 2026-05-07
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
Benzinga - 2026-05-07
Incyte Reports Phase 3 TRuE-AD4 Week 24 Data Showing Opzelura Cream Maintained High Rates Of Disease Control And Symptom Relief In Adults With Moderate Atopic Dermatitis At EADV 2026
Yahoo - 2026-05-04
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
Finnhub - 2026-05-04
Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Benzinga - 2026-05-03
Reported Sunday, Australia's TGA Approves Specialised Therapeutics' NIKTIMVO As First-In-Class CSF-1R Blocking Antibody For Chronic Graft-Versus-Host Disease
Yahoo - 2026-05-02
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings
Yahoo - 2026-05-01
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
SeekingAlpha - 2026-05-01
Incyte: Strong Business, But Risks Remain
Benzinga - 2026-04-29
Oppenheimer Maintains Perform on Incyte, Raises Price Target to $90
Yahoo - 2026-04-29
Incyte to Present at Upcoming Investor Conferences
Yahoo - 2026-04-29
Company News for Apr 29, 2026
Yahoo - 2026-04-29
Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...
SeekingAlpha - 2026-04-28
Incyte Corporation 2026 Q1 - Results - Earnings Call Presentation
Yahoo - 2026-04-28
Incyte (INCY) Q1 2026 Earnings Call Transcript
Yahoo - 2026-04-28
Incyte (INCY) Q2 2025 Earnings Transcript
Yahoo - 2026-04-28
Incyte Corporation Q1 2026 Earnings Call Summary
Yahoo - 2026-04-28
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales
Yahoo - 2026-04-28
Incyte Wavers As Growth Questions Plague Its Up-And-Coming Drug
SeekingAlpha - 2026-04-28
Incyte Corporation (INCY) Q1 2026 Earnings Call Transcript
Yahoo - 2026-04-28
Incyte Q1 Earnings Call Highlights
Yahoo - 2026-04-28
Compared to Estimates, Incyte (INCY) Q1 Earnings: A Look at Key Metrics
Finnhub - 2026-04-28
Incyte beats first-quarter estimates on strong demand for cancer drugs
Yahoo - 2026-04-28
Incyte Stock Reverses, Though Questions Face Its Key Growth Product
ChartMill - 2026-04-28
Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts
Finnhub - 2026-04-28
Transcript : Incyte Corporation, Q1 2026 Earnings Call, Apr 28, 2026
Yahoo - 2026-04-28
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Yahoo - 2026-04-28
Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations
Yahoo - 2026-04-28
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
Finnhub - 2026-04-28
Incyte : Q1 Financial Results (d630a12a b738 4bd7 a437 67eb7a808d0e)
Benzinga - 2026-04-28
Incyte Sees FY2026 Sales $4.770B-$4.940B vs $5.569B Est
Finnhub - 2026-04-28
Incyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
Finnhub - 2026-04-28
Incyte : Q1 2026 Financial and Corporate Update Presentation
Finnhub - 2026-04-28
Incyte Corporation Appoints Suketu Upadhyay as Chief Financial Officer, Effective May 4, 2026
Finnhub - 2026-04-28
Incyte Appoints Suketu Upadhyay as Executive Vice President, Effective May 4, 2026
Benzinga - 2026-04-28
Incyte Appoints Suketu (Suky) Upadhyay As Executive Vice President And CFO Effective May 4, 2026
Benzinga - 2026-04-28
CORRECTION: Incyte Q1 Adj. EPS $1.81 Beats $1.37 Estimate, Sales $1.273B Beat $1.217B Estimate.
Finnhub - 2026-04-28
Incyte: Q1 Earnings Snapshot
Benzinga - 2026-04-28